Search Orphan Drug Designations and Approvals
-
| Generic Name: | Zoledronate | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Zometa, Zabel | ||||||||||||||||
| Date Designated: | 08/18/2000 | ||||||||||||||||
| Orphan Designation: | Treatment of tumor induced hypercalcemia. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Novartis Pharmaceuticals Corp. 59 Route 10 East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Zoledronate |
|---|---|---|
| Trade Name: | Zometa, Zabel | |
| Marketing Approval Date: | 08/20/2001 | |
| Approved Labeled Indication: | Treatment of hypercalcemia of malignancy. | |
| Exclusivity End Date: | 08/20/2008 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







